La cadena de opciones muestra datos clave de las opciones de acciones de Lifecore Biomedical a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Lifecore Biomedical..

Lifecore Biomedical (NASDAQ:LFCR) Bolsa, Cadena de Opciones

Lifecore Biomedical

Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.

Lifecore Biomedical Inc

UBS analyst Laura Sutcliffe initiates coverage on Telix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLX#NASDAQ">TLX</a>) with a Buy rating and announces Price Target of $21.

News

Price Target

Initiation

Analyst Ratings

UBS Initiates Coverage On Telix Pharmaceuticals with Buy Rating, Announces Price Target of $21

HC Wainwright &amp; Co. analyst Emily Bodnar maintains Genelux (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLX#NASDAQ">GNLX</a>) with a Buy and lowers the price target from $32 to $30.

GNLX

HC Wainwright & Co. Maintains Buy on Genelux, Lowers Price Target to $30

BMO Capital analyst John Kim upgrades Independence Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRT#NYSE">IRT</a>) from Underperform to Market Perform and raises the price target from $19 to $21.

Upgrades

BMO Capital Upgrades Independence Realty Trust to Market Perform, Raises Price Target to $21

EYEN

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

WIIM

POOL

Pool Corp shares are trading higher after a 13F filing showed that Berkshire Hathaway added a new stake.

Domino's Pizza shares are trading higher after a 13F filing showed that Berkshire Hathaway added a new stake.

Baird analyst Shrenik Kothari maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Outperform and raises the price target from $385 to $425.

PANW

Baird Maintains Outperform on Palo Alto Networks, Raises Price Target to $425

ULTA

Ulta Beauty shares are trading lower after Berkshire Hathaway cut its position in the stock.

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) with a Buy and maintains $3 price target.

Reiteration

RNAZ

HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $3 Price Target

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/66585980a3067c00012c48c0/david-roman">Goldman Sachs analyst David Roman </a>initiated coverage on HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Neutral rating and announced a price target of $108. HealthEquity shares closed at $95.70 on Thursday. <a href="https://www.benzinga.com/quote/HQY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wolfe Research analyst Alexandria Hammond initiated coverage on Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) with an Underperform rating and announced a price target of $25. Pfizer shares closed at $26.02 on Thursday. <a href="https://www.benzinga.com/quote/PFE/analyst-ratings">See how other analysts view this stock.</a></li>
<li><a href="https://www.benzinga.com/insights/analyst-ratings/24/10/41494343/analyst-expectations-for-mastecs-future">Stifel analyst Brian Brophy</a> initiated coverage on EMCOR Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EME#NYSE">EME</a>) with a Buy rating and announced a price target of $600. EMCOR shares closed at $498.11 on Thursday. <a href="https://www.benzinga.com/quote/EME/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Redburn Atlantic analyst Harry Read initiated coverage on Insight Enterprises, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSIT#NASDAQ">NSIT</a>) with a Buy rating and announced a price target of $220. Insight Enterprises shares closed at $152.63 on Thursday. See how other analysts view this stock.</li>
<li>Wolfe Research analyst Alexandria Hammond initiated coverage on Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with an Outperform rating and announced a price target of $190. Johnson &amp; Johnson shares closed at $151.87 on Thursday. <a href="https://www.benzinga.com/quote/JNJ/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying JNJ stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="569" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15072028/image-169-1024x569.png" alt="" class="wp-image-650063" style="width:716px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15072028/image-169-1024x569.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15072028/image-169-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15072028/image-169-768x427.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15072028/image-169.png 1196w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/42000528/dow-dips-over-200-points-following-economic-reports-tesla-tumbles-on-potential-removal-of-ev-tax-credit-fear-index-remains-in-greed-zone">Dow Dips Over 200 Points Following Economic Reports, Tesla Tumbles On Potential Removal Of EV Tax Credit: Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

NSIT

This Johnson & Johnson Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Sol-Gel Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLGL#NASDAQ">SLGL</a>) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.13) by 92.31 percent. This is a 95.24 percent increase over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $5.36 million which beat the analyst consensus estimate of $2.69 million by 99.29 percent. This is a 2.42K percent increase over sales of $213.00 thousand the same period last year.

SLGL

Sol-Gel Technologies Q3 EPS $(0.01) Beats $(0.13) Estimate, Sales $5.36M Beat $2.69M Estimate

Baird analyst Wesley Golladay maintains Kite Realty Gr Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRG#NYSE">KRG</a>) with a Neutral and raises the price target from $26 to $29.

Baird Maintains Neutral on Kite Realty Gr Trust, Raises Price Target to $29

HC Wainwright &amp; Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) with a Buy and maintains $20 price target.

PSTX

HC Wainwright & Co. Reiterates Buy on Poseida Therapeutics, Maintains $20 Price Target

Baird analyst Jack Allen maintains MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) with a Outperform and lowers the price target from $8 to $4.

INKT

Baird Maintains Outperform on MiNK Therapeutics, Lowers Price Target to $4

Citigroup analyst Beatrice Lam downgrades Gogoro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GGR#NASDAQ">GGR</a>) from Buy to Neutral and lowers the price target from $2.3 to $0.5.

Downgrades

Citigroup Downgrades Gogoro to Neutral, Lowers Price Target to $0.5

HC Wainwright &amp; Co. analyst Sean Lee reiterates Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) with a Buy and maintains $8 price target.

PSTV

HC Wainwright & Co. Reiterates Buy on Plus Therapeutics, Maintains $8 Price Target

Baird analyst Joel Beatty maintains Immutep (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMP#NASDAQ">IMMP</a>) with a Outperform and raises the price target from $6 to $7.

IMMP

Baird Maintains Outperform on Immutep, Raises Price Target to $7

"The CHMP's positive opinion marks an important milestone for patients in Europe with non-epithelioid mesothelioma, who experience worse survival outcomes than patients with epithelioid mesothelioma," said Dr. Gregory Lubiniecki, vice president, oncology clinical research, Merck Research Laboratories. "The positive CHMP opinion moves us closer to offering a new first-line treatment option with a proven overall survival benefit for certain patients in the European Union with this difficult-to-treat cancer."

Merck Says European Medicines Agency's Committee for Medicinal Products For Human Use Approves KEYTRUDA (pembrolizumab), Anti-PD-1 Therapy, In Combination With Pemetrexed And Platinum Chemotherapy, For Adult  Patients With Unresectable Non-epithelioid Malignant Pleural Mesothelioma

Baird analyst Colleen Kusy maintains Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) with a Outperform and raises the price target from $32 to $40.

ELVN

Baird Maintains Outperform on Enliven Therapeutics, Raises Price Target to $40

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth downgrades Predictive Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>) from Buy to Neutral.

POAI

HC Wainwright & Co. Downgrades Predictive Oncology to Neutral

Lifecore Biomedical raises $24.3M through private placement

Lifecore Biomedical ( ($LFCR) ) has shared an update. Lifecore Biomedical, Inc. successfully closed a private placement of 5,928,775 shares of comm...

Lifecore Biomedical Raises $24.3M, Expands Capacity and Clientele

Lifecore Biomedical, Inc. (LFCR) Q1 2025 Earnings Call Transcript

Barrington analyst Michael Petusky has maintained their neutral stance on LFCR stock, giving a Hold rating on October 4. Michael Petusky's rating i...

Lifecore Biomedical: A Cautious Hold Amid Modest Growth and Financial Challenges

Lifecore Biomedical GAAP EPS of -$0.53, revenue of $24.7M

Lifecore (LFCR) Biomedical announced that it has appointed Thomas Guldager as vice president, operations. An experienced pharmaceutical industry pr...

Lifecore appoints Guldager as vice president, operations

Lifecore (LFCR) Biomedical announced that it will host a virtual investor day on Thursday, November 21, 2024, prior to market open. The event will ...

Lifecore to host virtual investor day on November 21

Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Lifecore Biomedical (LFCR – Research Report) today. The company's shares closed yesterd...

Craig-Hallum Sticks to Their Buy Rating for Lifecore Biomedical (LFCR)

Greenhaven Road Capital Q3 2024 Investor Letter

Lifecore Biomedical: Finally A 'Pure Play' CDMO Business

CLBT

CTLT

HGTY

LFCR

SBUX

Legal

Press Releases

LFCR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Lifecore Biomedical Selected by Lindy Biosciences to Support Process Development and Commercial Scale-Up for Innovative Microglassification Formulation Technology

Biotech

General

Lifecore Biomedical to Report Financial Results for First Quarter of Fiscal 2025 Prior to Market Open on October 4, 2024

Financing

Lifecore Biomedical Raises $24.3 Million in Private Placement of Common Stock

Earnings

Lifecore Biomedical Reports First Quarter of Fiscal 2025 Financial Results and Provides Corporate Update

Johnson Fistel LLP Investigates Lifecore Biomedical, Inc's Directors and Officers for Breach of Fiduciary Duties and Encourages Long Term Shareholders to Reach Out for Their Options

Comments

Lifecore Biomedical

Lifecore Biomedical (LFCR) Opciones

Lifecore Biomedical (NASDAQ:LFCR) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL